Individualized blood management for non-cardiac surgeries
Individualized Acute Normovolemic Hemodilution for Non-cardiac Surgery With Anticipated High-dose Red Cells Transfusion
This study tests whether a personalized blood management technique can help adults having non-cardiac surgeries avoid needing blood transfusions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | West China Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06399536 on ClinicalTrials.gov |
What this trial studies
This trial investigates the effects of individualized acute normovolemic hemodilution (ANH) on the need for red blood cell transfusions in adults undergoing non-cardiac surgeries with expected significant blood loss. The study aims to reduce the complications associated with allogeneic blood transfusions by employing a technique that dilutes blood volume while maintaining normal blood pressure. Participants will be randomly assigned to receive individualized ANH or standard care to evaluate the effectiveness of this approach in minimizing transfusion requirements.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 75 undergoing elective non-cardiac surgery with an anticipated need for more than 8 units of red blood cells.
Not a fit: Patients who refuse blood transfusions or have significant comorbidities such as cardiopulmonary insufficiency or renal impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the need for blood transfusions and associated complications during major surgeries.
How similar studies have performed: While ANH has shown mixed results in previous literature, this individualized approach may provide new insights and improvements in its application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing elective non-cardiac surgery with an anticipated red blood cells transfusion \>8 units (or 1600ml) * Aged 18\~75 years * Preoperative Hb level \> 120g/L for men and \> 110g/L for women. Exclusion Criteria: * Refusal of blood transfusion * Cardiopulmonary insufficiency * Cerebrovascular disease * Renal impairment * Hemoglobinopathies or blood system diseases * Other situations not suitable for inclusion in clinical trial.
Where this trial is running
Chengdu, Sichuan
- West China Hospital of Sichuan University — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Principal investigator: Ren Liao — West China Hospital
- Study coordinator: Ren Liao, M.D.
- Email: liaoren7733@163.com
- Phone: +86-18980602177
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.